3,577 trials (keyword fallback)
Thymoma · Thymic Carcinoma · Thymic Carcinoid
Primary: Objective Response Rate (Partial Response (PR)+Complete Response (CR)) to IMC-A12 Monotherapy in Patients With Advanced or Recurrent Thymoma or Thymic Carcinoma. — 0; 0…
Thymoma · Thymic Carcinoma
Primary: Number of Participants With a Partial Response — 2; 0 Participants
Locally Advanced Thymic Carcinoma · Metastatic Thymic Carcinoma · Recurrent Thymic Carcinoma
Primary: Progression-free Survival — 8; 7 Months
Thymoma · Thymus Cancer · Thymic Carcinoma
Primary: Overall Response Rate (ORR) — 0; 6; 6 Participants
Carcinoma, Transitional Cell
Primary: Objective Response Rate (ORR) - Central Assessment — 19.5; 21.6; 19.4; 23.8 percentage of participants — p==0.6991
Oral Squamous Cell Carcinoma · Neoadjuvant Chemotherapy
Primary: Clinical Response as Measured by RECIST 1.1. Criteria — 5; 5; 8; 7 Participants
Cancer, Solid Tumor
Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0…
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Thymoma · Thymic Carcinoma
Primary: Objective Response Rate (Complete and Partial Response) — 26.7; 9.1 percentage of participants
Breast Cancer
Primary: Cohort 1 and Cohort 4: Percentage of Participants With Objective Response (OR) as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors…
Biliary Tract Neoplasms · Liver Cancer · Hepatocellular Carcinoma
Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months
Neoplasms · Pancreatic Neoplasms
Primary: Objective Response (OR) (Partial Responses + Complete Responses) in Phase 2 Subjects of Short Infusion LMB-100+ Nab-paclitaxel — 1 Participants
COVID-19
Primary: Time to Participant Recovery — 6; 12 days
Advanced Bladder Urothelial Carcinoma · Advanced Ureter Urothelial Carcinoma · Metastatic Bladder Urothelial Carcinoma
Primary: Objective Response Rate (ORR) — 3; 4; 0; 2 Participants — p=0.428
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants